Snipr Biome - A Crispr Company

Snipr Biome - A Crispr Company company information, Employees & Contact Information

Updated June 2026

Quick answer

Snipr Biome - A Crispr Company is a Biotechnology Research company and founded in 2011. It has approximately 41 employees on record. Contact data was last refreshed in June 2026. Find Snipr Biome - A Crispr Company's verified employee emails, phone numbers, headquarters address, and key decision makers below.

We are the CRISPR and Gene Therapy of the Microbiome company! Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota. Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.

Company Details

Employees
41
Founded
2011
Address
Lersø Parkallé, Copenhagen,capital Region,denmark
Email
co****@****ome.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Copenhagen, Capital Region
Looking for a particular Snipr Biome - A Crispr Company employee's phone or email?

Snipr Biome - A Crispr Company Questions

News

SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance - SynBioBeta

SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial Resistance SynBioBeta

Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer - EU-Startups

Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer EU-Startups

Danish biotech company grabs €35 million Series B to develop CRISPR therapies for infections and resistance - ArcticStartup

Danish biotech company grabs €35 million Series B to develop CRISPR therapies for infections and resistance ArcticStartup

SNIPR Biome Secures €35M Series B for CRISPR Therapies - StartupHub.ai

SNIPR Biome Secures €35M Series B for CRISPR Therapies StartupHub.ai

Snipr Biome raises EUR millions despite a “difficult market” - medwatch.com

Snipr Biome raises EUR millions despite a “difficult market” medwatch.com

SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes - GlobeNewswire

SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes GlobeNewswire

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK - Cision News

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK Cision News

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark - SynBioBeta

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark SynBioBeta

SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy - Labiotech.eu

SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy Labiotech.eu

SNIPR BIOME commences dosing in Phase I trial of CRISPR-based therapy - Clinical Trials Arena

SNIPR BIOME commences dosing in Phase I trial of CRISPR-based therapy Clinical Trials Arena

MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics - MD Anderson Cancer Center

MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics MD Anderson Cancer Center

Clinical Update: SNIPR Biome Reports Positive Phase 1 Results For CRISPR-Armed Phage Therapy - CRISPR Medicine News

Clinical Update: SNIPR Biome Reports Positive Phase 1 Results For CRISPR-Armed Phage Therapy CRISPR Medicine News

SNIPR Biome Reports Good Initial "In-Human" Results for CRISPR Gene Therapy - Inside Precision Medicine

SNIPR Biome Reports Good Initial "In-Human" Results for CRISPR Gene Therapy Inside Precision Medicine

Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice - Nature

Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice Nature

SNIPR Biome receives funding from CARB-X to support - GlobeNewswire

SNIPR Biome receives funding from CARB-X to support GlobeNewswire

SNIPR Biome Receives CARB-X Funding to Test SNIPR001 in Phase 1B/2A Clinical Trial - CRISPR Medicine News

SNIPR Biome Receives CARB-X Funding to Test SNIPR001 in Phase 1B/2A Clinical Trial CRISPR Medicine News

Clinical Update: SNIPR Biome Doses First Human Subjects With CRISPR-Based Antibiotic - CRISPR Medicine News

Clinical Update: SNIPR Biome Doses First Human Subjects With CRISPR-Based Antibiotic CRISPR Medicine News

First cancer patient dosed in CRISPR-armed phage therapy - CRISPR Medicine News

First cancer patient dosed in CRISPR-armed phage therapy CRISPR Medicine News

Turning CRISPR into a bacteria killer. A new principle in antibiotics. Interview: Christian Grøndahl, CEO SNIPR BIOME: - CRISPR Medicine News

Turning CRISPR into a bacteria killer. A new principle in antibiotics. Interview: Christian Grøndahl, CEO SNIPR BIOME: CRISPR Medicine News

Win-win or naivete? – Snipr Biome to spill its secrets - medwatch.com

Win-win or naivete? – Snipr Biome to spill its secrets medwatch.com

AMR: Snipr Biome Aps raises €43m to programme pathogens for death - European Biotechnology Magazine

AMR: Snipr Biome Aps raises €43m to programme pathogens for death European Biotechnology Magazine

Top Snipr Biome - A Crispr Company Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant